» Download Public Reports
About 100 reports
- Company report
- October 2012
- 2 pages
... Million were still available on this line as of june 30th, 2012. 2/2 Press release launch of phase ii clinical study of inecalcitol in chronic lymphocytic leukemia (cll ...
October 2012
... Were still available on this line as of june 30th, 2012. Launch of phase ii clinical study of inecalcitol in chronic lymphocytic leukemia (cll) the 3.3 Million raised in march 2012 were ...
May 2013
... That dicobalt edetate only be given when the patient is tending to lose or has lost consciousness. Distamine penicillamine a disease modifying antirheumatic drug (dmard) used for the treatment of rheumatoid ...
December 2012
... That can lead to cirrhosis and liver cancer. The development of nafld/nash is associated with the pathophysiological process of insulin resistance in patients that are overweight and/or diabetic. Nafld ...
April 2013
... Of a pathologic oxygen supply dependency remains contro- versial. Study objective: to evaluate the relationship between oxygen delivery (do2) and oxygen consumption (vo2) during severe sepsis and to compare ...
September 2012
... Morbid conditions nci all mci dem p e r c e n t a g e risk factors for progression Does disease co-morbidity increase risk of dementia (2-years follow-up) in mci Overall, medical co-morbidity does not appear ...
October 2012
... Persistent and/or progressive chronic illness. Highest prevalence: hypertension, diabetes, hyperlipidemia, atherosclerosis, atrial fibrillation, hypothyroidism, arthritis, asthma Total cost band ...
November 2012
... And epigenetic status Epilepsy and other neurologic disorders Cardiovascular screening and function childhood cancer Multidisciplinary multidimensional aspects of sensory input, learning and behavior ...
January 2013
... If parallel changes in do2 and vo2 seen in a patient with critical illness reflect pathologic supply dependency, or just the normal cardiovascular re- sponse to acute changes in oxygen demand in patients ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 400 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
